CL2014003017A1 - Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo - Google Patents

Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo

Info

Publication number
CL2014003017A1
CL2014003017A1 CL2014003017A CL2014003017A CL2014003017A1 CL 2014003017 A1 CL2014003017 A1 CL 2014003017A1 CL 2014003017 A CL2014003017 A CL 2014003017A CL 2014003017 A CL2014003017 A CL 2014003017A CL 2014003017 A1 CL2014003017 A1 CL 2014003017A1
Authority
CL
Chile
Prior art keywords
heparinoid
interacting
treat
myelosuppressive effect
myelosuppressive
Prior art date
Application number
CL2014003017A
Other languages
English (en)
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Publication of CL2014003017A1 publication Critical patent/CL2014003017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
CL2014003017A 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo CL2014003017A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261644623P 2012-05-09 2012-05-09
US201261644556P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09

Publications (1)

Publication Number Publication Date
CL2014003017A1 true CL2014003017A1 (es) 2015-07-10

Family

ID=49549076

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014003017A CL2014003017A1 (es) 2012-05-09 2014-11-07 Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
CL2021000008A CL2021000008A1 (es) 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021000008A CL2021000008A1 (es) 2012-05-09 2021-01-04 Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)

Country Status (21)

Country Link
US (6) US9271999B2 (es)
EP (2) EP3785720A1 (es)
JP (3) JP6177885B2 (es)
KR (2) KR102165348B1 (es)
CN (3) CN113521093A (es)
AU (1) AU2013260101B2 (es)
BR (1) BR112014028094B1 (es)
CA (2) CA2872855C (es)
CL (2) CL2014003017A1 (es)
DK (1) DK2846809T3 (es)
EA (1) EA029382B1 (es)
ES (1) ES2848050T3 (es)
HK (1) HK1207574A1 (es)
HU (1) HUE053247T2 (es)
IL (1) IL235593B (es)
LT (1) LT2846809T (es)
MX (2) MX370567B (es)
PL (1) PL2846809T3 (es)
PT (1) PT2846809T (es)
SG (3) SG10201603059YA (es)
WO (1) WO2013169355A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
KR20160101898A (ko) * 2013-10-22 2016-08-26 캔텍스 파마슈티칼즈, 인크. 방사선 손상의 치료 및 예방 방법
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
CN107569486A (zh) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 孟鲁司特钠治疗血小板减少症的新用途
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
US20200237872A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
WO2021041532A1 (en) * 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
AU2020382214B2 (en) * 2019-11-13 2023-07-06 Taiho Pharmaceutical Co., Ltd. Novel salt of terphenyl compound
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
KR20230058289A (ko) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 혈액암 치료를 위한 글리세오플빈 병용요법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (fr) 1983-10-18 1986-09-12 Choay Sa Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
DE3422518A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
FR2584606A1 (fr) 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
WO1991015216A1 (en) 1990-04-05 1991-10-17 Kennedy Thomas P Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
WO1994018989A1 (en) 1993-02-22 1994-09-01 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
DE69731386T2 (de) 1996-07-29 2006-02-16 Paringenix, Inc., Tucson Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
IL131410A0 (en) 1997-02-15 2001-01-28 Proscript Inc Pharmaceutical compositions for treating infarcts through inhibition of nf-kappab
ATE260116T1 (de) 1997-05-30 2004-03-15 Arch Dev Corp P-selectin translokation ins vaskulare epitheliale lumen durch ionisierende strahlung
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
BR9915317A (pt) 1998-11-13 2001-08-07 Lilly Co Eli Método de tratar trombocitopenia induzida por heparina
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
WO2001019376A2 (en) 1999-09-13 2001-03-22 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US20050026811A1 (en) 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
JP5026655B2 (ja) * 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2003293122A1 (en) 2002-11-27 2004-06-23 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
WO2005089365A2 (en) 2004-03-16 2005-09-29 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
AU2005235455B2 (en) * 2004-04-22 2011-01-20 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (ja) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd 生理活性分子含有架橋ヘパリンゲル組成物
EP1906974A4 (en) 2005-07-22 2010-06-23 Univ California SELECTINE INHIBITOR HEPARIN COMPOSITIONS
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
EP1939278A4 (en) 2005-09-30 2009-06-03 Takara Bio Inc METHOD FOR PRODUCING A T CELL POPULATION
EA200870059A1 (ru) 2005-12-16 2008-12-30 ДиЭнПи КЭНАДА ИНК. Производные хитина для применения при гиперлипидемии
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
PT2043662E (pt) 2006-07-26 2015-11-25 Intrexon Corp Métodos e composições para tratamento de doença
EP2061504A4 (en) 2006-09-20 2010-01-27 Univ Johns Hopkins COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES
WO2008106584A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
PL2155188T3 (pl) * 2007-06-01 2014-03-31 Abraxis Bioscience Llc Sposoby i kompozycje do leczenia nawrotowego raka
JP2010534672A (ja) 2007-07-23 2010-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション 終末糖化産物受容体（ｒａｇｅ）の連結を阻止するための方法
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US20090238852A1 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
AU2009231634B2 (en) 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US20130034534A1 (en) 2009-09-29 2013-02-07 Philipp Kroneberg Method for treatment of patients with cystic fibrosis
CN102917711A (zh) 2010-03-12 2013-02-06 澳大利亚国立大学 硫酸乙酰肝素替代疗法
PL2550294T3 (pl) * 2010-03-24 2020-03-31 Progastrine Et Cancers S.À R.L. Profilaktyka nowotworu jelita grubego i nowotworu przewodu pokarmowego
EP3153173A1 (en) 2010-06-28 2017-04-12 Stemtech International, Inc. Methods and compositions for enhancing stem cell mobilization
MX2013006020A (es) * 2011-01-31 2013-10-01 Celgene Corp Composicion farmaceutica de analogos de citidina y metodos para su uso.
US20120196828A1 (en) 2011-02-01 2012-08-02 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
MX2014013049A (es) 2012-05-01 2015-03-19 Univ Duke Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
US11116819B2 (en) 2013-02-28 2021-09-14 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
KR20160101898A (ko) 2013-10-22 2016-08-26 캔텍스 파마슈티칼즈, 인크. 방사선 손상의 치료 및 예방 방법
WO2015061604A1 (en) 2013-10-24 2015-04-30 Thomas Kennedy Treating bacterial infections of the lung
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) * 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20160243168A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
WO2013169355A1 (en) 2013-11-14
CN104411316B (zh) 2018-05-01
CN113521093A (zh) 2021-10-22
JP2019026647A (ja) 2019-02-21
HUE053247T2 (hu) 2021-06-28
PT2846809T (pt) 2021-02-05
EA201492052A1 (ru) 2015-08-31
US20200038431A1 (en) 2020-02-06
CN104411316A (zh) 2015-03-11
LT2846809T (lt) 2021-01-25
CA2872855C (en) 2021-07-27
MX2019009437A (es) 2019-10-02
CA3122808A1 (en) 2013-11-14
BR112014028094A2 (pt) 2020-06-30
US20180296590A1 (en) 2018-10-18
MX370567B (es) 2019-12-17
AU2013260101A1 (en) 2014-12-18
CN108498532B (zh) 2021-07-23
PL2846809T3 (pl) 2021-07-26
JP6448694B2 (ja) 2019-01-09
IL235593A0 (en) 2015-01-29
EP2846809B1 (en) 2020-10-14
US11229664B2 (en) 2022-01-25
JP6726252B2 (ja) 2020-07-22
EP2846809A1 (en) 2015-03-18
KR20150023361A (ko) 2015-03-05
US20220354882A1 (en) 2022-11-10
KR102165348B1 (ko) 2020-10-14
SG11201407340YA (en) 2014-12-30
EP2846809A4 (en) 2015-12-30
EA029382B1 (ru) 2018-03-30
ES2848050T3 (es) 2021-08-05
JP2017105850A (ja) 2017-06-15
JP6177885B2 (ja) 2017-08-09
SG10201914117QA (en) 2020-02-27
KR102452803B1 (ko) 2022-10-07
US20130303481A1 (en) 2013-11-14
HK1207574A1 (en) 2016-02-05
CL2021000008A1 (es) 2021-06-11
JP2015521176A (ja) 2015-07-27
IL235593B (en) 2019-06-30
US20160213706A1 (en) 2016-07-28
SG10201603059YA (en) 2016-05-30
US20130323230A1 (en) 2013-12-05
DK2846809T3 (da) 2021-01-18
KR20200118510A (ko) 2020-10-15
CN108498532A (zh) 2018-09-07
EP3785720A1 (en) 2021-03-03
US8734804B2 (en) 2014-05-27
BR112014028094B1 (pt) 2022-03-03
CA2872855A1 (en) 2013-11-14
US9271999B2 (en) 2016-03-01
MX2014013633A (es) 2015-07-06
AU2013260101B2 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
CL2014003017A1 (es) Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo
BR112015013023A2 (pt) composição de limpeza de pele aquosa
DK2988791T3 (da) Tværbundet silke-hyaluronsyresammensætning
BR112014023200A2 (pt) uso de uma composição
BR112015021713A2 (pt) sonda para tratar uma insuficiência neuromuscular
BR112013008528A2 (pt) métodos para tratar psoríase
BR302012004175S1 (pt) Configuração aplicada em dispensador
BR302012004766S1 (pt) Configuracao aplicada em injetor médico
BR302013000698S1 (pt) Configuração aplicada em dispensador de água com filtro
FR3001392B1 (fr) Composition dermatologique amelioree
DK2583571T3 (da) Forbedringer i forbindelse med skødeskind
CO6880061A2 (es) Método para tratar el cáncer mediante el uso combinado de fármacos
BR302013001429S1 (pt) Configuração aplicada em estrutura para dispositivo
BR302013001713S1 (pt) Configuração aplicada em extremidade de espigão
UA27043S (uk) Ротор до гумозмішувача
GB201319102D0 (en) Improvements relating to auction mechanisms
ES1076450Y (es) Plantilla terapeutica con aceites esenciales de efecto potenciado
BR302012002624S1 (pt) Configuração aplicada em injetor de elastomero
FR3000401B1 (fr) Composition cosmetique/ dermatologique
TH1501001474A (th) วิธีการผลิตองค์ประกอบยาง
BR302012004499S1 (pt) Configuracao aplicada em mictório
BR302012005298S1 (pt) Configuracao aplicada em conjunto sanitario
BR302012004333S1 (pt) Configuracao aplicada em reômetro
BR302012003945S1 (pt) Configuração aplicada em barraca
BR302013002025S1 (pt) Configuração aplicada em máquina para preparar massa